X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs VENUS REMEDIES - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA VENUS REMEDIES ABBOTT INDIA/
VENUS REMEDIES
 
P/E (TTM) x 38.7 -7.0 - View Chart
P/BV x 9.2 0.1 8,361.3% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 ABBOTT INDIA   VENUS REMEDIES
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-18
VENUS REMEDIES
Mar-17
ABBOTT INDIA/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs6,110143 4,278.7%   
Low Rs3,99665 6,147.7%   
Sales per share (Unadj.) Rs1,552.2324.2 478.8%  
Earnings per share (Unadj.) Rs188.86.4 2,945.4%  
Cash flow per share (Unadj.) Rs196.440.6 484.1%  
Dividends per share (Unadj.) Rs55.000-  
Dividend yield (eoy) %1.10-  
Book value per share (Unadj.) Rs796.6366.0 217.7%  
Shares outstanding (eoy) m21.2512.34 172.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.30.3 1,015.7%   
Avg P/E ratio x26.816.2 165.1%  
P/CF ratio (eoy) x25.72.6 1,004.6%  
Price / Book Value ratio x6.30.3 2,234.3%  
Dividend payout %29.10-   
Avg Mkt Cap Rs m107,3761,282 8,374.9%   
No. of employees `0003.30.9 367.9%   
Total wages/salary Rs m3,937251 1,568.5%   
Avg. sales/employee Rs Th9,929.34,430.1 224.1%   
Avg. wages/employee Rs Th1,185.1278.0 426.4%   
Avg. net profit/employee Rs Th1,207.787.6 1,378.7%   
INCOME DATA
Net Sales Rs m32,9854,000 824.5%  
Other income Rs m1,17023 5,153.7%   
Total revenues Rs m34,1554,023 849.0%   
Gross profit Rs m5,245785 668.4%  
Depreciation Rs m162422 38.4%   
Interest Rs m38344 11.1%   
Profit before tax Rs m6,21542 14,762.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,203-37 -5,953.2%   
Profit after tax Rs m4,01279 5,072.2%  
Gross profit margin %15.919.6 81.1%  
Effective tax rate %35.4-87.9 -40.3%   
Net profit margin %12.22.0 615.2%  
BALANCE SHEET DATA
Current assets Rs m22,6552,606 869.3%   
Current liabilities Rs m6,6811,980 337.4%   
Net working cap to sales %48.415.6 309.5%  
Current ratio x3.41.3 257.7%  
Inventory Days Days65128 50.5%  
Debtors Days Days2943 67.6%  
Net fixed assets Rs m8355,353 15.6%   
Share capital Rs m213123 172.2%   
"Free" reserves Rs m16,7154,393 380.5%   
Net worth Rs m16,9284,516 374.8%   
Long term debt Rs m01,618 0.0%   
Total assets Rs m24,1628,291 291.4%  
Interest coverage x163.71.1 14,582.8%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x1.40.5 282.9%   
Return on assets %16.85.1 328.7%  
Return on equity %23.71.8 1,353.2%  
Return on capital %36.96.3 587.3%  
Exports to sales %00-   
Imports to sales %018.4 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA736 0.0%   
Fx inflow Rs m3690-   
Fx outflow Rs m3,807736 517.0%   
Net fx Rs m-3,438-736 466.9%   
CASH FLOW
From Operations Rs m1,527997 153.1%  
From Investments Rs m-2,148-461 465.7%  
From Financial Activity Rs m-1,024-571 179.4%  
Net Cashflow Rs m-1,646-35 4,688.3%  

Share Holding

Indian Promoters % 0.0 32.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 0.2 4,388.9%  
FIIs % 0.1 0.6 17.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 66.4 25.8%  
Shareholders   18,270 20,121 90.8%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   SANOFI INDIA  ASTRAZENECA PHARMA  STRIDES SHASUN LTD  STERLING BIOTECH  JUBILANT LIFE SCIENCES  

Compare ABBOTT INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day in Green; IT Stocks Lead Gains(Closing)

After opening the day in green, share markets in India witnessed positive trading activity throughout the day and ended the day in above the dotted line.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (4QFY18); Net Profit Up 137.9%

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 137.9% YoY). Sales on the other hand came in at Rs 8 bn (up 10.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2%

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

How to Avoid a 90% Loss Suffered by This Super Investor(The 5 Minute Wrapup)

Jul 12, 2018

Blindly following super investors is a dangerous game to play. Here's how you can avoid such mistakes.

The Answer to Your Wealth Worries: Small Caps (Especially Now)(Profit Hunter)

Jul 10, 2018

If you're worried about the markets - you are on the wrong track. This is opportunity - put your wealth-building hat on, instead - Richa shows you how...

The Multiple Problems with the Minimum Support Price (MSP) System(Vivek Kaul's Diary)

Jul 11, 2018

The price signals that MSP sends out, creates its own set of problems.

ICICI Pru Mutual Fund Tarakki Karega! - The Unethical Way?(Outside View)

Jul 11, 2018

PersonalFN explains how ICICI Prudential Mutual Fund flouted the norms of related party transactions while subscribing to the IPO of ICICI Securities.

PPF v/s Mutual Funds: Which Is Better?(Outside View)

Jul 10, 2018

PersonalFN highlights the key points of distinction between PPF and mutual funds.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Jul 20, 2018 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 5-YR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS